Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Realm Therapeutics PLC    PURI   GB00B3XBCR18

REALM THERAPEUTICS PLC (PURI)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Realm Therapeutics : Result of AGM

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/14/2018 | 12:08pm CEST

Realm Therapeutics Announces Results of 2018 Annual General Meeting

MALVERN, PA, June 14, 2018- Realm Therapeutics plc (AIM: RLM) a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announcesthat all Resolutions put to shareholders were duly passed at its Annual General Meeting held earlier today. Proxy figures will be displayed shortly on the Company's website at www.realmtx.com.

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signaling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development program utilizes the Company's proprietary immunomodulatory technology for the treatment of Atopic Dermatitis, and the Company is exploring its efficacy in other dermatology indications which include Acne Vulgaris, and Psoriasis, as well as other therapeutic areas. For more information on Realm Therapeutics please visit www.realmtx.com.

RNS-RLM

Contacts:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US: +44 (0) 20 3727 1000

US: +1 212 600 1902

Argot Partners

Stephanie Marks / Susan Kim

+1 212 600 1902

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

N+1 Singer (Nominated Adviser and Broker)

Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000

Disclaimer

Realm Therapeutics plc published this content on 14 June 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 14 June 2018 10:07:04 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REALM THERAPEUTICS PLC
06/14REALM THERAPEUTICS : Result of AGM
PU
05/31REALM THERAPEUTICS : Realm to Present at June Investor Conferences
PU
05/25REALM THERAPEUTICS : Completes Enrollment in Phase 2 Study of PR022 for Atopic D..
AQ
05/24REALM THERAPEUTICS : Enrollment complete for Phase 2 study of PR022
PU
05/23REALM THERAPEUTICS : Filing with US SEC to Facilitate Nasdaq Listing
PU
05/02REALM THERAPEUTICS : Final Results
PU
05/02REALM THERAPEUTICS : Realm Files Registration for Nasdaq Listing of ADS
PU
04/26REALM THERAPEUTICS : Notice of Results
PU
03/13REALM THERAPEUTICS : Provides Clinical Update, including Results from a Phase 2 ..
AQ
02/20REALM THERAPEUTICS : Presentation at RBC Healthcare Conference
PU
More news
Financials ( GBP)
Sales 2018 0,79 M
EBIT 2018 -
Net income 2018 -
Finance 2018 15,5 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 38,1x
EV / Sales 2019 56,8x
Capitalization 45,4 M
Chart REALM THERAPEUTICS PLC
Duration : Period :
Realm Therapeutics PLC Technical Analysis Chart | PURI | GB00B3XBCR18 | 4-Traders
Technical analysis trends REALM THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Managers
NameTitle
John Alexander Martin Chief Executive Officer & Executive Director
Charles Alexander Evan Spicer Non-Executive Chairman
Marella Thorell COO, CFO, Secretary & Executive Director
Christian Peters Chief Medical Officer
Joseph William Birkett Senior Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
REALM THERAPEUTICS PLC5.41%60
CELLTRION, INC.--.--%33 987
IQVIA HOLDINGS INC5.50%21 394
LONZA GROUP3.38%20 341
INCYTE CORPORATION-21.91%15 677
ALNYLAM PHARMACEUTICALS, INC.-15.15%10 836